Next-Generation Sequencing Platform -Ion Torrent™ Genexus System* by Thermo Fisher Scientific Makes its World Debut at the 2nd CIIE
Holds Potential to Advance Precision Medicine in the Clinic
During the 2nd CIIE, Thermo Fisher Scientific, the world leader in serving science, announced the launch of its Ion Torrent™ Genexus System, the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day. The company also introduced its Oncomine Precision Assay*, an innovative pan-cancer panel for the Genexus platform. The two help win many audience’s attention, especially those from industry professionals.
As the first fully integrated NGS platform, Ion Torrent™ Genexus System features an one-stop automated specimen-to-report workflow that delivers results with practically zero intervention in a single day, redefining the genomic profiling paradigm, and enables a future in which local hospitals can adopt NGS and provide the most advanced care with all-around genomic information. We can now envision a time in which patients at local hospitals will have faster access to comprehensive test results that can guide more effective, targeted therapy selection and improved health outcomes.
Ion Torrent™ Genexus™ System
Tony Acciarito, President of Thermo Fisher Scientific China, mentioned that, “Both the first and second CIIEs provide a great platform for us as a company to launch our new products and exchange supply and demand, and that’s why we choose the 2nd CIIE to launch Ion Torrent™ Genexus System. We hope that Thermo Fisher’s leading innovative science can empower the clinical practice of precision medicines, bring benefits to more Chinese patients, and support the goal of ‘Healthy China 2030’.”